Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Shanghai Junshi Bioscience is the lead sponsor of 31 current clinical trials in our China register. 17 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are JS207, Toripalimab and JS212. The most-studied condition is Hepatocellular Carcinoma.

ClinicalTrials.gov trials by status

Recruiting1755%
Not yet open26%
Active, closed1239%

Trials by phase

Phase 21342%
Phase 31135%
Phase 1516%
Phase 1/213%
Phase 2/313%

Clinical trials sponsored by Shanghai Junshi Bioscience

31 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer NCT06885385 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer Drugs: Capecitabine, JS015, JS207	Phase 2	Recruiting	2025-04	China
Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia NCT05621070 · ClinicalTrials.gov ↗ · Primary Hypercholesterolaemia and Mixed Dyslipidemia	Phase 3	Recruiting	2023-02	China
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) NCT06170489 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma Drugs: Bendamustine, Gemcitabine, JS004	Phase 3	Recruiting	2023-12	China
JS207 Combination Therapy in Triple-negative Breast Cancer NCT07045311 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer Drugs: 9MW2821, Albumin paclitaxel, JS207	Phase 2	Recruiting	2025-09	China
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour NCT06888830 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumours Drug: JS212	Phase 1/2	Recruiting	2025-04	China
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy NCT06868836 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, JS207	Phase 2	Recruiting	2025-03	China
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies NCT06839105 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor Drugs: AWT020, Bevacizumab, Capecitabine	Phase 1	Recruiting	2025-02	China
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study NCT05342194 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma Drugs: Cisplatin, Gemcitabine Hydrochloride, Lenvatinib	Phase 3	Recruiting	2023-06	China
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer NCT07309276 · ClinicalTrials.gov ↗ · Advanced Lung Cancer Drugs: JS207, JS212, JS213	Phase 2	Recruiting	2026-01	China
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy NCT06924606 · ClinicalTrials.gov ↗ · Advanced NSCLC Drugs: Docetaxel, JS004, JS207	Phase 2	Recruiting	2025-07	China
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study NCT07518160 · ClinicalTrials.gov ↗ · Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations	Phase 2	Recruiting	2026-04	China
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) NCT06095583 · ClinicalTrials.gov ↗ · Limited-stage Small Cell Lung Cancer (LS-SCLC) Drug: Toripalimab	Phase 3	Recruiting	2023-11	China
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors NCT07480733 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors Drugs: JS207, JS212, JS213	Phase 2	Recruiting	2026-04	China
JS212 Combination Therapies in Metastatic Colorectal Cancer NCT07503756 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer Drugs: Bevacizumab, Capecitabine, JS207	Phase 2	Recruiting	2026-04	China
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma NCT06954467 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: JS007, JS207	Phase 2	Recruiting	2025-05	China
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. NCT07284134 · ClinicalTrials.gov ↗ · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Drugs: Docetaxel, Irinotecan, JS107	Phase 3	Recruiting	2025-12	China
A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT07484724 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	2026-04	China
A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT07808827 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 3	Not yet open	2026-09	China
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer NCT07823348 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: Bevacizumab, JS007, JS207	Phase 3	Not yet open	2026-10	China
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC NCT06944470 · ClinicalTrials.gov ↗ · NSCLC Drugs: JS207, Paclitaxel	Phase 2	Active, closed	2025-05	China
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor NCT06022250 · ClinicalTrials.gov ↗ · Advanced Malignant Tumor Drug: JS207	Phase 1	Active, closed	2023-09	China
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors NCT06571422 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors Drugs: Bevacizumab, JS207, Toripalimab	Phase 1	Active, closed	2024-10	China
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC NCT06969027 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Active, closed	2025-06	China
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma NCT05618327 · ClinicalTrials.gov ↗ · Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Drug: JS203	Phase 1	Active, closed	2023-02	China
Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma NCT04848753 · ClinicalTrials.gov ↗ · Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma	Phase 3	Active, closed	2021-05	China
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma NCT07081022 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin's Lymphoma Drugs: Gemcitabine and oxaliplatin, JS203, Lenalidomide	Phase 2	Active, closed	2025-08	China
JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） NCT06505837 · ClinicalTrials.gov ↗ · Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer	Phase 3	Active, closed	2024-07	China
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer NCT05180734 · ClinicalTrials.gov ↗ · Gastric or Esophagogastric Junction Adenocarcinoma	Phase 3	Active, closed	2022-02	China
Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection NCT03859128 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drug: Toripalimab	Phase 2/3	Active, closed	2019-03	China
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors NCT05502393 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drugs: Capecitabine, JS107, Oxaliplatin	Phase 1	Active, closed	2022-07	China
Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC NCT04523493 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma (HCC)	Phase 3	Active, closed	2020-06	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Shanghai Junshi Bioscience trials

28 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Shanghai Junshi Bioscience trials

28 conditions

Hepatocellular Carcinoma3 Advanced Malignant Solid Tumors2 Advanced Colorectal Cancer1Primary Hypercholesterolaemia and Mixed Dyslipidemia1Hodgkin Lymphoma1NSCLC1Advanced Malignant Tumor1Triple-negative Breast Cancer1 Diffuse Large B-Cell Lymphoma1 Non-small Cell Lung Cancer1Advanced Malignant Solid Tumours1Non-squamous Non-small Cell Lung Cancer1Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma1Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma1Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor1B-cell Non-Hodgkin's Lymphoma1Intrahepatic Cholangiocarcinoma1Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer1Advanced Lung Cancer1Advanced NSCLC1Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations1Gastric or Esophagogastric Junction Adenocarcinoma1Limited-stage Small Cell Lung Cancer (LS-SCLC)1Advanced Solid Tumors1

By trial register

Register	Trials	Recruiting
Clinical trials in China	31	17

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Hepatocellular Carcinoma

Sponsor	Trials
Sun Yat-sen University	23
The First Affiliated Hospital with Nanjing Medical University	4
Chinese PLA General Hospital	4
Akeso	3
Fujian Provincial Hospital	3
Zhongda Hospital	3
Guangxi Medical University	3
Replimune	2
HistoSonics	2
Teclison	2

Sponsors with the most current trials registered for this condition.

Questions about Shanghai Junshi Bioscience trials

How many clinical trials does Shanghai Junshi Bioscience sponsor?

Shanghai Junshi Bioscience is the lead sponsor of 31 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Junshi Bioscience trials recruiting?

Yes. 17 of its 31 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Junshi Bioscience testing?

Its current trials name 28 drugs and biologicals as interventions. The most frequent are JS207 (12), Toripalimab (9), JS212 (5), Oxaliplatin (5) and Bevacizumab (4). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Shanghai Junshi Bioscience clinical trials